26 May 2023: Articles
RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101
Unknown etiology, Educational Purpose (only if useful for a systematic review or synthesis)
Jessica M. Goss B* , Pamela Hair A , Parvathi S. Kumar A , Ulrich Thienel A , Kenji Cunnion A , Alexander Ellis ADOI: 10.12659/AJCR.939803
Am J Case Rep 2023; 24:e939803
Table 2. Subject 1504 Autoantibody panel.
| Visit | Test (unit) | Result | Normal reference range |
|---|---|---|---|
| Screening | Anti-double stranded DNA (IU/mL) | 0–4 | |
| Antinuclear antibodies | Negative | ||
| Cardiolipin IgG antibody (U/mL) | 0–20 | ||
| Cardiolipin IgM antibody (U/mL) | 0–20 | ||
| Ribonucleoprotein antibody (AI) | 0.2 | 0–1 | |
| Sjogren’s SS-A antibody (AI) | 0–1 | ||
| Sjogren’s SS-B antibody (AI) | 0–1 | ||
| Smith antibody (AI) | 0–1 | ||
| Day -1 | Antidrug antibody | Negative | |
| Day 6 | Antidrug antibody | Negative | |
| Anti-double stranded DNA (IU/mL) | 0–4 | ||
| Antinuclear antibodies | Negative | ||
| Cardiolipin IgG antibody (U/mL) | 0–20 | ||
| Cardiolipin IgM antibody (U/mL) | 0–20 | ||
| Ribonucleoprotein antibody (AI) | 0.2 | 0–1 | |
| Sjogren’s SS-A antibody (AI) | 0–1 | ||
| Sjogren’s SS-B antibody (AI) | 0–1 | ||
| Smith antibody (AI) | 0–1 | ||
| Follow-up | Anti-double stranded DNA (IU/mL) | 0–4 | |
| Antidrug antibody | Negative | ||
| Antinuclear antibodies | Negative | ||
| Cardiolipin IgG antibody (U/mL) | 0–20 | ||
| Cardiolipin IgM antibody (U/mL) | 0–20 | ||
| Ribonucleoprotein antibody (AI) | 0.2 | 0–1 | |
| Sjogren’s SS-A antibody (AI) | 0–1 | ||
| Sjogren’s SS-B antibody (AI) | 0–1 | ||
| Smith antibody (AI) | 0–1 | ||
| * Follow-up visit: Up to 27 days after discharge on Day 6 (Day 30±3 days, Day 27 through Day 33). | |||